Questar Downgraded Due to Valuation and 3 Stock Analyses to Track

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC): Current price $5.42

Cyclacel Pharmaceuticals announced the issuance of United States Patent No. U.S. 8,349,792 and European Patent No 2,101,790. Both patents include claims to combination treatment of Sapacitabine, the Company’s lead product candidate, with Histone Deacetylase inhibitors. The patents provide exclusivity until June 2029 and December 2027, respectively.


Questar Corporation (NYSE:STR): Current price $23.27

Questar Corporation was downgraded by UBS to Neutral due to valuation.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.


Synchronoss Technologies, Inc. (NASDAQ:SNCR): Current price $29.91

After Synchronoss Technologies announced that they had obtained a major new customer in India, Stifel sees the deployment as a major step forward for Synchronoss as this is the company’s first deal in an emerging market. The firm notes that they will also be the company’s first major cloud deployment and they maintain a $36 price target and Buy rating on the shares.


Chicago Bridge & Iron Company N.V. (NYSE:CBI): Current price $51.99

UBS raised Chicago Bridge & Iron Company’s price target, citing their strong 2014 outlook and Shaw accretion. Shares are Buy rated.


Don’t Miss: Who Holds the Most Gold?